DJIA 17,098.45 0.00 0.00%
NASDAQ 4,580.27 0.00 0.00%
S&P 500 2,003.37 0.00 0.00%
market minute promo

GlaxoSmithKline (NYSE: GSK)



company name or ticker
Company Photos
(Click to zoom)

Were There Any Silver Linings in GlaxoSmithKline Stock's Earnings Failure?

It was a rough quarter for GlaxoSmithKline. Were there any silver linings?

Glaxo (GSK) Slips on Disappointing Q2 Earnings, Cuts View - Analyst Blog

3 Game-Changing Stories That Shook Investors: Inovio Pharmaceuticals, Gilead Sciences, and GlaxoSmit

The health care sector saw a flurry of major news yesterday. Here are three key stories that investors may have missed.

Pre-Market Most Active for Jul 24, 2014 : FB, NOK, F, AAL, GSK, ANGI, GOV, ALU, GM, QCOM, ARIA, AAP

Pre-Market Most Active for Jul 24, 2014 : FB, NOK, F, AAL, GSK, ANGI, GOV, ALU, GM, QCOM, ARIA, AAPL

Jim Cramer's 'Mad Money' Recap: Unconventional Wisdom

What Will Puma Biotechnology Inc's $700 Million Man Do Next?

A sale to Johnson & Johnson, Pfizer, Roche, or one of the other big pharmas seems like the most likely outcome for Puma Biotechnology Inc.

Is Inovio Undervalued After Positive HPV Therapy Results?

GlaxoSmithKline's (GSK) CEO Andrew Wittyon Q2 2014 Results - Earnings Call Transcript

Wednesday's ETF with Unusual Volume: PPH

FDA Approves Gilead Sciences Drug for 3 Cancers

The company's tablet, Zydelig, works by blocking signals inside some cancer cells that allow them to grow and survive.